Evidence map›Paper›PMID 30887866›Full record

ArticleLeukemia & lymphoma2019

Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib.

Satoko Oka, Kazuo Ono, Masaharu Nohgawa

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Satoko OkaDivision of Hematology, Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.
Kazuo OnoDivision of Pathology, Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.
Masaharu NohgawaDivision of Hematology, Japanese Red Cross Society Wakayama Medical Center , Wakayama , Japan.
Japanese Red Cross Society Wakayama Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, the effects of immunophenotyping on the prognoses of patients with MM treated with bortezomib as induction therapy were investigated. A total of 118 patients with MM were examined, and the prognostic significance of the immunophenotyping and other factors were investigated. Immature and plasmablastic cell types and high-risk cytogenesis were more frequently observed in patients with CD33+ and MPC-1-. CD33+ and MPC-1- have potential as prognostic factors and correlated with lower progression-free survival and overall survival in a Kaplan-Meier analysis. Moreover, the present results demonstrated that at the relapse of disease, the percentage of CD33 increased (median 48.7%) and MPC-1 decreased (median 14.1%), respectively, therefore, both of these antigens may be associated with the refractory disease status. The present study showed that the expression of CD33 and MPC-1 in neoplastic plasma cells from patients with MM was associated with patient prognosis independent of other prognostic factors.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBortezomibDexamethasoneDrug Resistance, NeoplasmFemaleFlow CytometryHumansImmunophenotypingInduction ChemotherapyKaplan-Meier EstimateMaleMiddle AgedBiomarkers, TumorBortezomibCD33 protein, humanDexamethasoneMitochondrial Membrane Transport ProteinsMonocarboxylic Acid TransportersMPC1 protein, humanSialic Acid Binding Ig-like Lectin 3bortezomibCD33immatureMPC-1Multiple myeloma

Identifiers

PMID30887866
OpenAlexW2924414902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.